文献速递肿瘤 PET/CT

唾液腺癌患者根治性调强放疗前原发肿瘤18F-FDG PET/CT的SUVmax预测治疗结局

Pretreatment Primary Tumor SUVmax on 18F-FDG PET/CT Images Predicts Outcomes in Patients With Salivary Gland Carcinoma Treated With Definitive Intensity-Modulated Radiation Therapy.
PubMed 文献 · Clin Nucl Med · 2017-01-01

该回顾性研究纳入2007至2014年46例接受根治性调强放疗的唾液腺癌患者,分析放疗前18F-FDG PET/CT原发肿瘤SUVmax与治疗结局的关系。中位随访54个月后,5年局部区域无进展生存率77%、无远处转移生存率75%、无进展生存率63%、总生存率61%。多因素分析显示SUVmax是局部区域无进展生存和无进展生存的唯一独立预测因素,体能评分和SUVmax均与总生存独立相关。

要点

  • 46例唾液腺癌患者根治性调强放疗前原发肿瘤中位SUVmax为7.4(范围2.3-23.6)。
  • SUVmax≥7.4组5年局部区域无进展生存、无远处转移生存和总生存均显著低于SUVmax<7.4组。
  • 多因素分析中SUVmax是局部区域无进展生存(P=0.023)和无进展生存(P=0.003)的唯一独立预测因素。

核心结论

  • 根治性调强放疗前原发肿瘤18F-FDG PET/CT的SUVmax可预测唾液腺癌患者的治疗结局。
  • 当需要保留器官功能和外观时,根治性调强放疗是一种有效的治疗策略。

研究设计与样本

  • 回顾性研究纳入2007至2014年46例接受根治性调强放疗的唾液腺癌患者,放疗前均行18F-FDG PET/CT。
  • 大多数肿瘤位于小唾液腺(n=35,76%),46%(n=21)的患者为不可切除疾病,中位放疗剂量为72 Gy。
  • 分析临床病理参数及放疗前原发肿瘤SUVmax与治疗结局的关系。

主要发现

  • 中位随访54个月后,5年局部区域无进展生存率77%、无远处转移生存率75%、无进展生存率63%、总生存率61%。
  • 原发肿瘤中位SUVmax为7.4(范围2.3-23.6),使5年无进展生存预后意义最大化的最佳截断值为7.4(P=0.006)。
  • SUVmax≥7.4组5年局部区域无进展生存率(P=0.007)、无远处转移生存率(P=0.046)和总生存率(P=0.013)均显著低于SUVmax<7.4组。
  • 多因素分析显示SUVmax是局部区域无进展生存(P=0.023)和无进展生存(P=0.003)的唯一独立预测因素。
  • 多因素分析显示体能评分(P<0.001)和SUVmax(P=0.022)均与总生存独立相关。

关键数值与推荐

  • 原发肿瘤SUVmax最佳截断值为7.4,该值使5年无进展生存的预后意义最大化(P=0.006)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to investigate the prognostic significance of F-FDG uptake in salivary gland carcinoma (SGC) patients treated with definitive intensity-modulated radiation therapy (IMRT). METHODS: We retrospectively examined 46 SGC patients who received pretreatment F-FDG PET/CT and definitive IMRT between 2007 and 2014. Most tumors were located in the minor salivary glands (n = 35 [76%]). Forty-six percent (n = 21) of the participants had unresectable disease. The median radiation dose was 72 Gy. Treatment outcomes were examined in relation to clinicopathologic parameters and pretreatment primary tumor SUVmax on F-FDG PET/CT. RESULTS: After a median follow-up of 54 months, the 5-year locoregional progression-free survival (LRPFS), distant metastasis-free survival, progression-free survival (PFS), and overall survival (OS) rates were 77%, 75%, 63%, and 61%, respectively. The median primary tumor SUVmax was 7.4 (range, 2.3-23.6), and the optimal cutoff value that maximized the prognostic significance for 5-year PFS was 7.4 (P = 0.006). Patients with a high SUVmax (≥7.4) had significantly lower 5-year LRPFS (P = 0.007), distant metastasis-free survival (P = 0.046), and OS (P = 0.013) rates than those with a low SUVmax (<7.4). Multivariate analyses identified SUVmax as the only independent predictor of LRPFS (P = 0.023) and PFS (P = 0.003), whereas both the performance score (P < 0.001) and SUVmax (P = 0.022) were independently associated with OS. CONCLUSIONS: Pretreatment primary tumor SUVmax on F-FDG PET/CT predicts treatment outcomes in SGC patients. Definitive IMRT is an effective treatment strategy when organ function and cosmesis need to be preserved.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hsieh CE, Ho KC, Hsieh CH, et al. Pretreatment Primary Tumor SUVmax on 18F-FDG PET/CT Images Predicts Outcomes in Patients With Salivary Gland Carcinoma Treated With Definitive Intensity-Modulated Radiation Therapy. Clin Nucl Med. 2017. PMID: 28650891. doi:10.1097/RLU.0000000000001740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。